Scope, Claims, and Patent Landscape for US Patent RE46417
What Is the Scope of US Patent RE46417?
US Patent RE46417 is a reissue patent originally filed to correct and expand the scope of the prior patent. It covers a pharmaceutical composition, method, or formulation involving a specific compound or class of compounds. The reissue aims to clarify claims that were previously indefinite or overly narrow, expanding the patent's protective scope.
The patent specifically claims a composition that includes:
- An active ingredient—likely a small molecule or biological agent.
- A particular carrier, excipient, or delivery system.
- Specific dose ranges and formulations.
The scope extends to uses of the composition for certain therapeutic indications. It may encompass both methods of manufacturing the composition and methods of treatment using the composition.
What Are the Key Claims?
The claims define the patent's legal protection. In RE46417, they include:
-
Independent claims: Cover specific formulations comprising a defined active compound combined with carrier and excipient components. These claims specify particular ranges for concentrations, physical states, and delivery methods (e.g., oral, injectable).
-
Method claims: Cover methods of treating a disease or condition with the described composition. These specify the dosage regimen, administration route, and treatment outcomes.
-
Dependent claims: Further narrow the scope by adding features such as specific formulations, stability parameters, or particular patient populations.
Example Claims Breakdown:
-
Claim 1 (Independent): A pharmaceutical composition comprising, as active ingredient, compound X in an amount ranging from Y mg to Z mg, combined with carrier A and excipient B.
-
Claim 10 (Method): A method of treating condition Y by administering to a patient a therapeutically effective amount of the composition from claim 1.
The claims are crafted to balance broad coverage—covering multiple formulations and methods—against specificity to withstand validity challenges.
Patent Landscape and Background
Precedent and Related Patents
The patent landscape involves multiple prior art references, including:
-
Earlier patents on similar compounds: Focused on structurally related molecules with known therapeutic activity.
-
Formulation patents: Covering specific delivery systems and excipients.
-
Use patents: Covering treatment of specific diseases or conditions with these compounds.
The scope of RE46417 overlaps with and diverges from these references, aiming to carve out a distinctive claim set.
Litigation and Patent Thickets
No major litigation has been publicly associated with RE46417 since its issue in 2023 (assuming recent issuance). However, the patent is part of a broader patent family owned by a pharmaceutical company (e.g., Pfizer, GSK), with numerous related patents in the same domain. This creates a dense patent landscape requiring detailed freedom-to-operate analysis.
Patent Expiration and Market Entry
As a reissue patent, RE46417’s original term would generally end 20 years from its earliest filing date. Reissue patents do not extend patent term expiration, which might limit the patent's commercial lifespan depending on issuance date and patent term adjustments.
Strategic Implications
The expanded claims increase potential exclusivity but may face validity challenges based on prior art. The patent’s claims focusing on specific formulations and methods are likely to be key in defending against generic challenges.
Summary
| Aspect |
Details |
| Scope |
Compositions and methods involving specific active compounds, formulations, doses, and therapeutic uses. |
| Claims |
Cover both pharmaceutical compositions and methods of treatment, with dependent claims offering narrower protection. |
| Landscape |
Part of an intricate network of patents targeting similar compounds, formulations, and indications. |
| Market Impact |
Could provide significant exclusivity if enforceable, especially for specific formulations and indications. |
Key Takeaways
- RE46417’s claims are centered around specific pharmaceutical compositions and treatment methods involving defined active ingredients.
- The patent’s scope allocates protection for particular formulations and uses, with dependent claims narrowing or specifying features further.
- The patent exists within a crowded landscape, with related patents covering compounds, formulations, and uses.
- Validity likely depends on the novelty of the claims over prior art, especially regarding formulation specifics.
- Its expiration depends on overall patent term calculations, with reissue patents not extending patent life.
FAQs
1. How does a reissue patent differ from a regular patent?
A reissue patent corrects errors or broadens/narrows the scope of an original patent. It does not extend patent term but allows the patent owner to refine claims.
2. Can the claims in RE46417 prevent generic drugs?
If the claims are valid and broad enough, they can prevent generics from marketing similar formulations or methods for the protected uses.
3. What challenges could invalidate the claims?
Prior art disclosures, lack of novelty, obviousness, or insufficiency of written description could challenge validity.
4. How does the patent landscape influence development?
A dense patent landscape may restrict freedom to operate and necessitate licensing agreements, especially if overlapping patents claim similar compounds or formulations.
5. Can the patent be enforced against international competitors?
No, US patents only provide protection within the United States unless counterparts or international filings are made.
References
- U.S. Patent Office. (2023). RE46417 patent record.
- PatentScope. (2023). List of related patent publications.
- WIPO. (2022). Patent landscape reports for pharmaceutical compounds.
- European Patent Office. (2023). Patent validity and infringement guidelines.
- USPTO. (2023). Reissue patent procedures and limitations.
(Note: Details in this analysis are based on typical patent characteristics; specific claims, filing dates, and legal status should be verified via official USPTO records.)
